



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 21-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 27-09-2008 TO BE PUBLISHED 22-10-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 21-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 27-9-2008 TO BE PUBLISHED 22-10-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1123/2008	<u>22-9-2008</u> ACTARIS S. A.S., France (Priority 25-9-07 France)	“Distributor for a rotary distribution drive diaphragm gas meter”
1124/2008	ACTARIS S. A.S., France (Priority 25-9-07 France)	“rotary distribution drive diaphragm gas meter”
1125/2008	ACTARIS S. A.S., France (Priority 25-9-07 France)	“diaphragm gas meter”
1126/2008	ACTARIS S. A.S., France (Priority 25-9-07 France)	“Distributor cover for rotary distribution drive diaphragm gas meter”
1127/2008	Abbott GmbH& Co, KG. Germany (Priority 20-3-08 PCT/EP)	“Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT ₆ receptor”
1128/2008	Sanofi-Aventis France (Priority 22-9-06 France) Divisional	“ An acid addition salt of a substituted 2-aryl-6-phenylimidazo[1,2-a]pyridine compound”
1129/2008	<u>23-9-2008</u> Tajmahal Sports Company, Sialkot, Pakistan	“A novel UT12-panels football”
1130/2008	VA TECH WABAG GmbH, Austria (Priority 03-10-07 Austria)	“Process and apparatus for reducing biofouling on membranes of pressure-driven membrane separation processes”
1131/2008	Ortoff Engineers, Ltd. USA (Priority 18-10-07 USA)	“Hydrocarbon gas processing”

1132/2008	Boehringer Ingelheim International GmbH Germany (Priority 25-9-07 Europe)	“Dispensing device (CAT)”
1133/2008	1. Shahid Naveed 2. Abdullah Malik and 3. Naveed Ramzan Lahore, Pakistan	“Scrubbing gases with a novel spray nozzle suitable for wet scrubbers”
1134/2008	1. Abdullah Malik 2. Shahid Naveed and 3. Zeshan Nawaz Lahore, Pakistan	“Shedding ash with novel grate suitable for down draft gasifier”
	<u>24-9-2008</u>	
1135/2008	Novartis AG, Switzerland (Priority 28-9-07 USA)	Galenical formulations of organic compounds”
1136/2008	Takeda Pharmaceutical Company, Ltd. Japan (Priority 28-9-07 Japan)	“5-membered heterocyclic compound”
1137/2008	Novartis AG, Switzerland (Priority 28-9-07 USA)	“Galenical formulations of organic compounds”
1138/2008	Glaxo Group Limited, United Kingdom (Priority 22-3-1996 USA) Divisional	“Pharmaceutical composition comprising VX478 and a water soluble vitamin E compound”
	<u>25-9-2008</u>	
1139/2008	Uster Technologies AG, Switzerland (Priority 26-9-07 Switzerland)	“A device and method for measuring the mass or thickness of a lap at the infeed of a card”
1140/2008	AstraZeneca AB, Sweden (Priority 02-10-07 USA)	“Package 043”

141/2008	AstraZeneca AB, Sweden (Priority 04-10-07 USA)	“Novel compounds 008”
1142/2008	Schering Corporation, USA (Priority 28-9-07 USA)	“Gamma secretase modulators”
1143/2008	Bayer CropScience AG, Germany (Priority 02-10-07 Europe)	“Method for improving plant growth”
1144/2008	Celanese International Corporation USA (Priority 27-9-07 USA)	“Method and apparatus for making acetic acid with improved purification”
1145/2008	Boehringer Ingelheim International GmbH Germany (Priority 28-9-07 Germany)	“New compounds”
1146/2008	P2i Limited, United Kingdom (Priority 25-9-07 UK)	“Vapour delivery system”
1147/2008	P2i Limited, United Kingdom (Priority 25-9-07 UK)	“Vapour delivery system”
1148/2008	Takeda Pharmaceutical Company, Limited. Japan (Priority 25-9-07 USA)	“Polo-like kinase inhibitors”
	<u>26-9-2008</u>	
1149/2008	Lexicon Pharmaceuticals, Inc. USA (Priority 28-9-07 USA)	“Solid forms of (S)-ethyl 2-amino-3-(4-(2- amino-6-(R)-1-(4-chloro-2-(3-methyl-1H- pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)- primidine-4-yl)phenyl)propanoate and methods of their use”
1150/2008	Jadhav Uttamrao Hanumantrao,	“An architectural concept”

India
(Priority 18-12-07 India)

- | | | |
|-----------|--|---|
| 1151/2008 | Sanofi-Aventis
France
(Priority 28-9-07 France) | “Nicotinamide derivatives their preparation
and their therapeutic application” |
| 1152/2008 | Novartis AG,
Switzerland
(Priority 28-9-07 USA) | “Organic compounds” |
| 1153/2008 | Otsuka Pharmaceutical
Co,
Ltd.
Japan
(Priority 26-9-07 Japan) | “Metered dose inhaler” |
| | <u>27-9-2008</u> | |
| 1154/2008 | 1. Dr. Nighat Afza,
2. Muhammad Aijaz
Anwar,
3. Dr. Shazia Yasmeen,
4. Rashid Ali Ali Khan
5. Mahboob Ali Kalhoro,
6. Agha Nisar Ahmed
PCSIR, Labs, Karachi | “A process for the production of zinc gluconate
syrup-A dietary supplement” |
| 1155/2008 | 1. Dr. Nighat Afza,
2. Mahboob Ali Kalhoro,
3. Rashid Ali Ali Khan
4. Dr. Shazia Yasmeen,
5. Muhammad Aijaz
Anwar,
6. Dr. Sadia Ferheen | “A process for the production of caffeine free
energy drink” |

††††††††††††††††

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


493/2000 Novartis AG.,
Switzerland

“Aromatic ethanolamine compound”

(C07D, 215/26)


139804

A compound of formula I



where

Ar is a group of formula II



R¹ is hydrogen, hydroxy, or C₁-C₁₀-alkoxy;
R² and R³ are each independently hydrogen or C₁-C₁₀-alkyl;
R⁴, R⁵, R⁶ and R⁷ are each independently hydrogen, halogen, cyano, hydroxy, C₁-C₁₀-alkoxy, phenyl, C₁-C₁₀-alkyl, C₁-C₁₀-alkyl substituted by one or more halogen atoms or one or more hydroxy or C₁-C₁₀-alkoxy groups, C₁-C₁₀-alkyl interrupted by one or more hetero atoms, C₂-C₁₀-alkenyl, tri-C₁-C₁₀-alkylsilyl, carboxy, C₁-C₁₀-alkoxycarbonyl, or -CONRⁿR¹², where R¹¹ and R¹² are each independently hydrogen or C₁-C₁₀-alkyl, or R⁴ and R⁵, R⁵ and R⁶, or R⁶ and R⁷ together with the carbon atoms to which they are attached denote a 5- or 6-membered carbocyclic ring or a 5- or 6-membered O-heterocyclic ring containing one or two oxygen atoms;

R⁸ is -NHR¹³ where R¹³ is hydrogen, C₁-C₁₀-alkyl or -COR¹⁴ where R¹⁴ is hydrogen, or R¹³ is -SO₂R¹⁷ where R¹⁷ is C₁-C₁₀-alkyl or C₁-C₁₀-alkyl interrupted by one or more hetero atoms, and R⁹ is hydrogen, or R⁸ is -NHR¹⁸ where -NHR¹⁸ and R⁹, together with the carbon atoms to which they are attached, denote a 6-membered N-heterocycle;

R¹⁰ is -OR¹⁹ where R¹⁹ is hydrogen;
X is C₁-C₁₀-alkyl;
n is 1 or 2;

q and r are each zero or 1, the sum of q+r 1 or 2; and the carbon atom marked with an asterisk* has the R or S configuration, or a mixture thereof, when R₁ is hydroxy or alkoxy.


402/2002 Novartis AG.,
Switzerland

“Substituted dipeptide compound”

(C07K, 5/06, A61K, 31/22)

139805

Compound of the formula



Wherein R, R1, COOR2, R3-R7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.


518/2002 Agouron
Pharmaceuticals,
Inc.,
USA.

“(R)-3-((2S,3S)-2-hydroxy-3-{[1-(3-hydroxy-2-methyl-phenyl)-methanoyl]-amino}-4-phenylbutanoyl)-5,5-dimethyl-thiazolidine-4-carboxylic acid allylamide”

(C07D, 277/06, A61K, 38/55)

139806

Compound of the formula:



Where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. The compound, as well as pharmaceutical composition containing the compound useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic method for preparing such compound are also described.

449/2003 Smithkline
Beecham
Corporation,
USA.

”3’-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-OXO-4H-pyrazol-4-ylideno]hydrazine]-2’-hydroxy-[1,1’-biphenyl]-3-carboxylic acid bis-(monoethanolamine)”

(CO7C, 243/10)

139807

An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid.


149/2005 Boehringer
Ingelheim
International
GmbH.,
Germany

“A substituted carboxylic acid amide, the preparation thereof, pharmaceutical compositions containing the compound”

(CO7D, 233/58)

139808

The present invention relates to new substituted carboxylic acid amide of general formula



Wherein A, B and R¹ to R⁵ are defined in the specification, the tautomer the enantiomer, the diastereomer which have valuable properties.

195/2005 Saudi Basic
Industries
Corporation,
Saudi Arabia

“A process for the production of polyethylene terephthalate from terephthalic acid and ethylene glycol”

(CO8G, 63/28)

139809

The present invention relates to a process for the production of polyethylene terephthalate from terephthalic acid and ethylene glycol, comprising the steps of:

- (a) preparing a catalyst composition consisting of an antimony compound, being present such that the elemental antimony content is in a range of 15 ppm to less than 150 ppm and a zinc compound, being present such that the elemental zinc content is in a range of 40 to 160 ppm, wherein the ppm amounts by weight are based on the theoretical yield of the polyethylene terephthalate:
- (b) placing the catalyst composition, the terephthalic acid and the ethylene glycol in a vessel: and
- (c) reacting the terephthalic acid and the ethylene glycol in an esterification step and a polycondensation step to obtain polyethylene terephthalate.

④④④④④④

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139439	Bayer aktiengesellschaft. Germany.	344/1997
139440	Jassen Pharmaceutica N.V., Belgium	398/1997
139441	Janssen Pharmaceutica N.V. Belgium.	399/1997
139442	Wyeth Holdings Corporation. USA.	794/1998
139443	Bayer Aktiengesellschaft., Germany	824/1998
139444	Pfizer Products Inc, USA.	376/2000
139445	Pfizer Inc. USA.	891/2000
139446	Pfizer Products Inc., USA.	1133/2000
139447	Wyeth , USA.	1023/2003
139448	Wyeth Holdings Corporation. USA	791/2006
139449	Wyeth, USA.	1009/2006
139450	Pfizer Products Inc., USA.	1185/2007
139451	Pfizer Products Inc. , USA.	1186/2007

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488